Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome

(2019) Pavel Jindra et al.   Clinical Lymphoma Myeloma & Leukemia

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

(2018) Li Xuan et al.   CANCER

Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

(2018) Richard F. Schlenk et al.   BLOOD

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

(2017) Alexander E Perl et al.   LANCET ONCOLOGY

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

(2016) Steven Knapper et al.   BLOOD

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia

(2014) Yi-Bin Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

(2013) M. Pratcorona et al.   BLOOD

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

(2013) A. Galanis et al.   BLOOD

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis

(2012) Salut Brunet et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics

(2009) Tara K Gregory et al.   Journal of Hematology & Oncology

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE